How Glaxo Wellcome contributes to the avoidance of publication bias

Gibbs T.

Introduction:
Objectives:
Methods:
Results:
Discussion: In 1997, Glaxo Wellcome expressed a clear intent to create a climate where the evidence for prescribing our products is clear. In 1998, our Clinical Trials Register was launched with the specific objective to help professionals, undertaking systematic reviews, by reducing publication bias. Since then Glaxo Wellcome has taken further policy initiatives to complement the register; a commitment to publish all studies; the inclusion of a unique identifier in all publications so that the publication can easily be linked to the entry in the trial register. Glaxo Wellcome will continue to work with the Cochrane Collaboration to ensure that our clinical research is not only credible but accessible, thereby ensuring our medicines are used to best effect, to improve patient care.

Rome 1999 O51